A Nutritional Formulation for Cognitive Performance in Mild Cognitive Impairment: A Placebo-Controlled Trial with an...

Area of Science:

• Neurology
• Nutritional Science
• Gerontology

Background:

• Mild cognitive impairment (MCI) is a precursor to dementia.
• Nutraceuticals offer a potential avenue for cognitive support.
• Previous research suggests efficacy in other cognitive states.

Purpose of the Study:

• To evaluate the efficacy of a specific nutraceutical formulation (NF) in individuals with MCI.
• To assess cognitive changes over a 12-month period (6-month double-blind, 6-month open-label).

Main Methods:

• Thirty-four individuals with MCI were randomized to receive either NF or placebo for 6 months.
• NF comprised folate, alpha-tocopherol, B12, S-adenosyl methionine, N-acetyl cysteine, and acetyl-L-carnitine.
• An open-label extension followed, with all participants receiving NF.

Main Results:

• The NF group showed significant improvement on the Dementia Rating Scale (DRS; effect size >0.7).
• The NF group maintained performance on CLOX-1, while the placebo group declined.
• Placebo participants improved on DRS and stabilized on CLOX-1 during the open-label phase.

Conclusions:

• The nutraceutical formulation (NF) demonstrates efficacy in improving cognitive function in individuals with MCI.
• NF may help mitigate cognitive decline associated with MCI.
• Findings support NF as a potential intervention for cognitive health in aging populations.